McKesson Q1 2027 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Increased 8% to $105.4 billion.

Adjusted Earnings Per Share (EPS): Rose 20% to $9.93, exceeding expectations.

Operating Profit: $1.7 billion, a 16% increase, driven by growth in North American pharmaceutical and oncology segments.

Gross Profit: Increased 13% to $3.7 billion.

Operating Expenses: Increased 10% to $2.1 billion, reflecting investments for growth.

Free Cash Flow: Negative $372 million, improved from the previous year’s $1 billion decline.

Share Repurchases: $2.5 billion, including $2.25 billion through an accelerated program.

Liquidity: $10 billion in total liquidity, with $5.2 billion in cash and equivalents.

2Strategic Updates and Business Highlights

Leadership Transition: Kenny K. Cheung appointed as new CFO, emphasizing a focus on disciplined execution and capital allocation.

AI Initiatives: McKesson hosted an AI training session to enhance team capabilities in an AI-enabled environment.

Oncology and Multispecialty Growth: Revenue increased 33%, driven by both organic growth and the acquisition of Core Ventures.

North American Distribution: Strong growth supported by stable fundamentals and investments in a new regional distribution center.

Medical Surgical Solutions Separation: Progress made in the planned separation, with a strategic minority investment from Apollo Funds.

3Forward Guidance and Outlook

Adjusted EPS Guidance: Raised to $44.20 - $45 from $43.80 - $44.60.

Revenue Growth Expectation: 5% to 9% for the fiscal year.

Operating Profit Growth Expectation: 9% to 13%.

Segment Outlook:

North American Pharmaceuticals: Revenue growth of 4% to 8%.

Oncology and Multispecialty: Revenue growth of 14.5% to 18.5%.

Prescription Technology Solutions: Revenue growth of 2.5% to 6.5%.

Medical Surgical Solutions: Revenue growth of 1% to 6%.

4Bad News, Challenges, or Points of Concern

Market Dynamics: Lower branded pharmaceutical pricing due to wholesale acquisition cost decreases and branded to generic conversions impacted revenues.

Free Cash Flow Trends: Despite improvements, free cash flow remains negative and has shown a declining trend over the past two years.

Regulatory Risks: Ongoing monitoring of policy changes, particularly regarding the 340B program and IRA Part B, which could impact the business landscape.

5Notable Q&A Insights

North American Pharmaceutical Growth: Strong performance attributed to increased prescription volumes, though lower branded pricing affected revenue without significantly impacting operating profit.

Oncology and Multispecialty Performance: Growth driven by existing provider solutions, new business wins, and successful integration of acquired entities.

GLP-1 Medications: Continued robust growth expected, with a vibrant cash market and stable coverage dynamics.

Quarterly Cadence: Seasonal trends indicate Q4 will be the largest quarter; investments and product launches will influence performance throughout the year. Overall, McKesson's Q1 2027 results reflect strong operational performance and strategic execution, with a positive outlook for the remainder of the fiscal year, despite some challenges in market dynamics and cash flow trends.